|
US2020397790A1
|
|
Uridine Phosphorylase (UPase) Inhibitors for Treatment of Liver Conditions
|
|
WO2020214537A1
|
|
Modulators of ras gtpase
|
|
US2020239479A1
|
|
Pyrazolopyrimidine Modulators of RAS GTPase
|
|
WO2020036982A1
|
|
Methods and compositions for treating mucositis
|
|
WO2020036975A1
|
|
Methods and compositions for reducing fluorouracil induced toxicity
|
|
WO2020036974A1
|
|
Methods and compositions for reducing radiation induced toxicity
|
|
WO2020033413A2
|
|
Modulators of ras gtpase
|
|
CN105636434A
|
|
Non-mammalian RAS transgenic animal model
|
|
CN104667279A
|
|
Methotrexate Adjuvants To Reduce Toxicity And Methods For Using The Same
|
|
CN102006775A
|
|
Doxorubicin adjuvants to reduce toxicity and methods for usingsame
|
|
WO2004106496A2
|
|
Methods and compositions for use in homologous recombination in plant cells
|
|
US2004043486A1
|
|
Methods and compositions for use in homologous recombination
|
|
IL164912D0
|
|
Methods and compositions for use in homologous recombination
|
|
CN1774506A
|
|
Methods and compositions for use in homologous recombination
|
|
EP1435963A2
|
|
Reduced toxicity cisplatin formulations and methods for using the same
|
|
AU2002331884A1
|
|
Animal integration vector and methods for its use
|
|
CA2381144A1
|
|
In vivo high throughput toxicology screening method
|
|
US6365129B1
|
|
Invivo high throughput toxicology screening method
|
|
US6316690B1
|
|
Non-mammalian transgenic animal model for cellular proliferative diseases
|
